Merck KGaA raises 2026 outlook as life science & AI chip boom power strong Q1 growth
The company’s shares of confidence were underlined by an upgraded 2026 outlook, with Merck now expecting annual net sales of up to €21.4 billion and EBITDA pre of as much as €6.1 billion




















